期刊文献+

回顾性分析年龄与拮抗剂方案移植时机的相关性

下载PDF
导出
摘要 目的比较不同年龄阶段采用拮抗剂方案促排卵治疗患者新鲜周期与全胚冷冻后第一次冻融胚胎复苏移植(frozen-thawed embryo transfer,FET)后的妊娠结局,探讨年龄与拮抗剂方案移植时机的相关性。方法回顾性分析2017年7月至2019年12月在我院生殖科采用拮抗剂方案促排卵治疗后行体外受精-胚胎移植(IVF-ET)/卵胞浆内单精子显微注射(ICSI)治疗的274例患者284个IVF/ICSI移植周期的临床数据。将患者根据女方年龄分为两组,A组女方年龄<40岁,B组女方年龄≥40岁。两组间又分为新鲜周期移植与全胚冷冻后第一次冻融胚胎复苏移植两亚组,其中新鲜周期组为(A1组127个周期、B1组73个周期),复苏移植组为(A2组62个周期、B2组22个周期)。比较不同年龄组患者的促排卵情况和妊娠结局。结果比较A1/A2组患者、B1/B2组患者平均年龄、不孕年限、BMI、bFSH/bLH、AMH、Gn总量、Gn天数(天)、获卵数、受精率、成熟卵率、D3天优胚率、移植胚胎数、原继发不孕构成比、受精方式构成比、至少移植1枚优质胚胎构成比,差异无统计学意义(均P>0.05)。两亚组临床结局的比较发现,A2组患者的临床妊娠率、生化妊娠率、胚胎种植率比A1组高,差异有统计学意义(P<0.05);而B1和B2组的生化妊娠率、临床妊娠率、胚胎种植率未见统计学差异(P>0.05)。结论拮抗剂方案助孕后年龄<40岁患者行全胚冷冻后复苏移植临床妊娠率可能更高,而≥40岁患者可以考虑新鲜胚胎移植。
出处 《江西医药》 CAS 2020年第10期1488-1491,共4页 Jiangxi Medical Journal
基金 江西省卫生健康委科技计划项目,编号20204771。
  • 相关文献

二级参考文献47

  • 1Gleicher N, Weghofer A, Barad D. Too old for IVF:are we discrimin- ating against older women? [J]. J Assist Reprod Genet, 2007,24(12):639-644.
  • 2Ching-Chien,Chang,PhD,et al. Prospective controlled study to evaluate laboratory and clinical outcomes of oocyte vitrification obtained in in vitro fertilization patients aged 30 to 39 years [J]. Fertility and Sterility, 2013,99(7) : 1891 - 1897.
  • 3American Society for Reproductive Medicine. Aging and infertility in women[J]. Ferlil Steril, 2006, 86(5 Suppl 1):S248-S252.
  • 4Ilse A, Jvan Rooij, Laszlo FJM, M Bancsi, et al. Women older than 40 years of age and those with elevated folliele-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization[J]. Fertility and Sterility, 2003,79(3) : 482-488.
  • 5American Society for Reproductive Medicine. Age-related fertility decline :a committee opinion [J]. Fertil Steril,2008,90 (5 Suppl) : S154-S155.
  • 6Pellestor F, Andreo B, Anahory T, et al. The occurrence of aneuploidy in human:lessons from the cytogenetic studies of human oocytes [J]. Eur J Med Genet, 2006,49(2) : 103-116.
  • 7Jinsong Xiao,Shuang Chang, Shuangyun Chen. The effectiveness of gonadotropin-releasing hormone antagonist in poor ovarian responders undergoing in vitro fertilization:a systematic review and meta-analysis[J]. Fertility and Sterility, 2013,100(6): 1594-1601.
  • 8BroekmansFJ, Weima SM&teVelde ER. A randomized comparison of two ovarian stimulation protocols with gonadetropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commenci- ng recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard longGnRH agonist protocol [J]. J Clin Endocrinol Metab, 2003,88(9): 4510.
  • 9Escudero E, Bosch E, Crespo J, et al. Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients[J]. Fertil Steril, 2004, 81 (3):562-566.
  • 10Oberye J J, Mannaerts BM, Huisman JA, et al. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers[J]. Fertil Steril, 1999, 72(6):1006-1012.

共引文献50

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部